Celltrion snaps up Lilly's NJ drug substance plant for $330M in tariff mitigation move, pledges to retain employees

URLhttps://www.fiercepharma.com/manufacturing/celltri
SourceFierce Pharma
Date Published09/23/2025
Author Name Fraiser Kansteiner

Additional Reshoring Information:

Company/Division name Celltrion
Parent companyCelltrion Holdings
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2025
Year reshoring implemented or to be implemented:2025
Domestically, the work will be done:In-house
Capital investment ($):330
Country(ies) from which reshored:Korea, South
City reshored to:Branchburg
State(s) reshored to:NJ
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharmaceuticals
What non-domestic negative factors made offshoring less attractive?Tariffs
Find Reshoring Articles